文献速递肿瘤 PET/CT核素与放射性配体治疗

18FDG PET/CT早期评估非小细胞肺癌免疫治疗反应:非典型演变模式的频率与临床意义

18FDG PET/CT in the early assessment of non-small cell lung cancer response to immunotherapy: frequency and clinical significance of atypical evolutive patterns.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-11-23

这项前瞻性研究纳入50例转移性非小细胞肺癌患者,在帕博利珠单抗或纳武利尤单抗治疗前及治疗7周后行FDG-PET,采用PERCIST评估反应。首次PERCIST进展但无临床恶化的患者继续治疗并在3个月时再次PET,区分假性进展、免疫分离反应和免疫均匀进展;后两者与持续临床获益相关。

要点

  • 治疗7周PERCIST评估中58%患者为进展,但其中超过三分之一最终获得持续临床获益。
  • 首次PERCIST进展后继续治疗者,3个月PET识别出32%假性进展和26%免疫分离反应。
  • 免疫分离反应和假性进展患者均获得临床获益,而免疫均匀进展患者无获益。

核心结论

  • 首次PERCIST进展后继续治疗的患者中,后续PET可识别超过一半的免疫分离反应和假性进展,两者均与免疫治疗临床获益强相关。

研究设计与样本

  • 前瞻性研究纳入50例转移性非小细胞肺癌患者,在帕博利珠单抗或纳武利尤单抗开始前及治疗7周后行FDG-PET(PETinterim1),采用PERCIST等标准评估肿瘤反应。

主要发现

  • PETinterim1时42%(21/50)患者为反应或疾病稳定,其中18/21获得持续临床获益;58%(29/50)为进展,但11/29最终获得持续临床获益。
  • 首次PERCIST进展的29例中19例继续治疗,PETinterim2显示免疫均匀进展42%(8/19)、免疫分离反应26%(5/19)、假性进展32%(6/19)。
  • 免疫均匀进展患者均未获得持续临床获益,而免疫分离反应和假性进展患者均获得临床获益。

关键数值与推荐

  • 假性进展定义为PETinterim2上PERCIST反应/稳定而PETinterim1为进展。
  • 持续临床获益定义为治疗持续超过6个月。

临床怎么用

  • 对于首次PERCIST进展但无临床恶化的非小细胞肺癌患者,可考虑继续免疫治疗并在3个月时复查FDG-PET以识别假性进展或免疫分离反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This prospective study aimed (1) to assess the non-small cell lung cancer (NSCLC) evolutive patterns to immunotherapy using FDG-PET and (2) to describe their association with clinical outcome. DESIGN: Fifty patients with metastatic NSCLC were included before pembrolizumab or nivolumab initiation. FDG-PET scan was performed at baseline and after 7 weeks of treatment (PETinterim1) and different criteria/parameters of tumor response were assessed, including PET response criteria in solid tumors (PERCIST). If a first PERCIST progressive disease (PD) without clinical worsening was observed, treatment was continued and a subsequent FDG-PET (PETinterim2) was performed at 3 months of treatment. Pseudo-progression (PsPD) was defined as a PERCIST response/stability on PETinterim2 after an initial PD. If a second PERCIST PD was assessed on PETinterim2, a homogeneous progression of lesions (termed immune homogeneous progressive-disease: iPDhomogeneous) was distinguished from a heterogeneous evolution (termed immune dissociated-response: iDR). A durable clinical benefit (DCB) of immunotherapy was defined as treatment continuation over a 6-month period. The association between PET evolutive profiles and DCB was assessed. RESULTS: Using PERCIST on PETinterim1, 42% (21/50) of patients showed a response or stable disease, most of them (18/21) reached a DCB. In contrast, 58% (29/50) showed a PD, but more than one-third (11/29) were misclassified as they finally reached a DCB. No standard PETinterim1 criteria could accurately distinguished responding from non-responding patients. Treatment was continued in 19/29 of patients with a first PERCIST PD; the subsequent PETinterim2 demonstrated iPDhomogeneous, iDR and PsPD in 42% (8/19), 26% (5/19), and 32% (6/19), respectively. Whereas no patients with iPDhomogeneous experienced a DCB, all patients with iDR and PsPD reached a clinical benefit to immunotherapy. CONCLUSION: In patients with a first PD on PERCIST and treatment continuation, a subsequent PET identifies more than half of them with iDR and PsPD, both patterns being strongly associated with a clinical benefit of immunotherapy.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Humbert O, Cadour N, Paquet M, et al. 18FDG PET/CT in the early assessment of non-small cell lung cancer response to immunotherapy: frequency and clinical significance of atypical evolutive patterns. Eur J Nucl Med Mol Imaging. 2019. PMID: 31760467. doi:10.1007/s00259-019-04573-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。